In GC, a peptide mimicking vgll4 function was used in therapy as a YAP antagonist, and vgll4 was found to directly compete with YAP for binding to TEADs in GC; the peptide mimicking vgll4 function potently inhibited tumor growth in vitro and in vivo [82]. Here, VGLL4 is linked to gastric cancer.